Outlook Therapeutics Inc
NASDAQ:OTLK
Intrinsic Value
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employ... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of OTLK.
Outlook Therapeutics Inc's market capitalization is 176.8m USD.
OTLK stock price is 8.19 USD.
OTLK.
OTLK. Open DCF Valuation
OTLK. Open Relative Valuation
OTLK has upside potential of 397% compared to the average analyst price target.
Open Wall St Estimates
OTLK has negative Free Cash Flow for the last twelve months.
OTLK has negative Operating Income for the last twelve months.
OTLK has negative Net Income for the last twelve months.
OTLK's ROE (Return on Equity) has significantly increased in the last 3 years from -62 308% to 1 200%.
OTLK's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 319% to -681%, and is approaching profitability.
OTLK's ROE (Return on Equity) for the past 12 months is very high and is equal to 1 200%.
OTLK's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -681%.
OTLK's long-term liabilties (46m USD) exceed its long-term assets (22m USD).
OTLK's short-term liabilties (46m USD) exceed its short-term assets (20m USD).
OTLK has negative three-year average ROE (Return on Equity): -4 908%. The company is not efficient at transforming stockholders' equity into net income.
OTLK has negative three-year average ROIC (Return on Invested Capital): -962%. The company is not efficient at using invested capital to generate operating income.
OTLK's D/E (Debt to Equity) is very low and is equal to 0.
OTLK's Altman Z-Score is very low and is equal to -37.97.
OTLK doesn't generate enough operating income (-48m USD) to safely cover interest payments on its debt (10 USD).
Fundamental Analysis
Outlook Therapeutics Inc
Balance Sheet Decomposition
Outlook Therapeutics Inc
| Current Assets | 20.4m |
| Cash & Short-Term Investments | 10.4m |
| Other Current Assets | 10m |
| Non-Current Assets | 1.3m |
| Long-Term Investments | 796.5k |
| PP&E | 15k |
| Other Non-Current Assets | 484.3k |
| Current Liabilities | 46m |
| Accounts Payable | 3.5m |
| Accrued Liabilities | 4.1m |
| Other Current Liabilities | 38.4m |
| Non-Current Liabilities | 59.6k |
| Other Non-Current Liabilities | 59.6k |
Earnings Waterfall
Outlook Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-47.8m
USD
|
|
Operating Income
|
-47.8m
USD
|
|
Other Expenses
|
-3.7m
USD
|
|
Net Income
|
-51.5m
USD
|
Free Cash Flow Analysis
Outlook Therapeutics Inc
OTLK Profitability Score
Profitability Due Diligence
Outlook Therapeutics Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Outlook Therapeutics Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
OTLK Solvency Score
Solvency Due Diligence
Outlook Therapeutics Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
Outlook Therapeutics Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OTLK Price Targets Summary
Outlook Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
OTLK
is 40.71 USD
with a low forecast of 25.25 USD and a high forecast of 63 USD.
Ownership
OTLK Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
OTLK Price
Outlook Therapeutics Inc
| Average Annual Return | -1.77% |
| Standard Deviation of Annual Returns | 37.01% |
| Max Drawdown | -94% |
| Market Capitalization | 176.8m USD |
| Shares Outstanding | 21 584 300 |
| Percentage of Shares Shorted | 7.43% |
Company Profile
Outlook Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 9 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
You don't have any saved screeners yet
